Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $844.5M | $1,108.5M | $1,084.2M | $1,566.1M | $1,902.2M | $2,011.5M | $2,559.1M | $3,185.8M | $3,691.7M | $4,475.7M | $4,716.1M | $5,186.7M | $5,633.9M | $5,785.3M | $6,116.1M | $5,832.9M | $6,444.9M | $7,590.1M | $7,853.6M | $12.1B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novo Nordisk A/S's last 12-month Net Income is $13.8B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novo Nordisk A/S's Net Income growth was 27.7%. The average annual Net Income growth rates for Novo Nordisk A/S have been 27.1% over the past three years, 18.7% over the past five years.
Over the last year, Novo Nordisk A/S's Net Income growth was 27.7%, which is higher than industry growth of (0.1%). It indicates that Novo Nordisk A/S's Net Income growth is Good.